Icovamenib development timeline includes Phase II updates and 52-week data in 2026

Traders Union
All News
Companies
Biomea Fusion outlines 2026 Icovamenib goals

Top Stories

Editors' Picks

Crypto

Financial News

Currencies

Market Voices

Companies

Regulators

Central Banks

03.04.2026

Icovamenib development timeline includes Phase II updates and 52-week data in 2026 — Biomea Fusion outlines 2026 Icovamenib goals

Biomea Fusion has detailed its expected milestones for the Icovamenib drug programs in 2026. The company is planning to deliver 52-week follow-up data from its COVALENT-112 study in the second quarter of 2026.

Additionally, Biomea Fusion aims to present Phase II clinical data for both the COVALENT-211 and COVALENT-212 studies in the fourth quarter of the same year. These milestones mark the next crucial steps as the company advances its targeted oncology pipeline.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Biomea Fusion has previously pursued icovamenib as a novel therapy targeting beta cell restoration in diabetes, according to Dr. Alice Cheng’s assessment in an earlier company update. The company also scheduled an oral presentation on icovamenib’s clinical data at ATTD 2006, with a focus on diabetes innovation earlier this year. These developments set the stage for Biomea Fusion’s next phase of clinical milestones.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Shifting priorities: Governments back mining as businesses turn to AI

By Eugene Komchuk
19 hours ago

Shifting priorities: Governments back mining as businesses turn to AI

Editors' Picks

Intel's comeback: Apple, Trump and the AI bet

By Mikhail Vnuchkov
Yesterday

Intel's comeback: Apple, Trump and the AI bet

Editors' Picks

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

By Oleg Tkachenko
17.06.2026

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Editors' Picks

All Editors' Top Picks

Latest Biomea Fusion News

Team Fusion pinpoints this year leading trends at ADA2026 event

By Andreas Kristo
18.06.2026

Team Fusion pinpoints this year leading trends at ADA2026 event

Companies

Biomea Fusion unveils new icovamenib data showing durable insulin secretion gains in T1D and T2D

By Igor Krasulya
06.06.2026

Biomea Fusion unveils new icovamenib data showing durable insulin secretion gains in T1D and T2D

Companies

Icovamenib GLP-1 therapy combination evaluated in Biomea Fusion academic study

By Eugene Komchuk
03.06.2026

Icovamenib GLP-1 therapy combination evaluated in Biomea Fusion academic study

Companies

All Biomea Fusion News

Eugene Komchuk
19 hours ago

Shifting priorities: Governments back mining as businesses turn to AI

Mikhail Vnuchkov
Yesterday

Intel's comeback: Apple, Trump and the AI bet

Oleg Tkachenko
17.06.2026

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Anastasiia Chabaniuk
16.06.2026

Toncoin becomes Gram: Why Durov restored token's original name

Kyle Torpey
15.06.2026

Why Tether flipping Ethereum is a pivotal moment for crypto

Daria Chernytska
35 min ago

FBI faces rising risks from foreign crypto scams, Wendy O warns

Yaroslav Dmytrenko
1 hour ago

Bitcoin-to-altcoin asset flows are declining, Ki Young Ju notes

Oleg Tkachenko
1 hour ago

Andy Constan: Market now interprets task forces as signals for rate policy

Mikhail Vnuchkov
1 hour ago

AI-driven stocks dominate S&P 500 at record 45 percent, Adam Khoo notes

Hanna Syniavska
1 hour ago

Fred Krueger: Strategy should launch Bitcoin-backed fixed maturity securities for 2030 to 2034

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Andrey Mastykin
14 hours ago

Iran tightens rules for Hormuz ship transit

Iran tightens rules for Hormuz ship transit

Hanna Syniavska
18 hours ago

U.S.-Iran talks postponed as truce outlook dims

U.S.-Iran talks postponed as truce outlook dims

Olga Shendetskaya
19 hours ago

Oil gains after new U.S.-Iran talks are called off

Oil gains after new U.S.-Iran talks are called off

Igor Krasulya
20 hours ago

Goldman Sachs revises gold forecast as Fed stays hawkish

Goldman Sachs revises gold forecast as Fed stays hawkish

Eugene Komchuk
21 hours ago

Kalshi prepares for IPO amid revenue growth

Kalshi prepares for IPO amid revenue growth

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft under pressure as technical picture remains weak

Anton Kharitonov
Now

Apple consolidates after AI rally as investors await new growth catalyst

Anton Kharitonov
Now

Bitcoin struggles for direction amid macroeconomic uncertainty

Anton Kharitonov
Now

WTI recovers after selloff as downside risks remain

Anton Kharitonov
Now

Natural gas maintains upward bias amid supply risks and seasonal demand

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.